In the study [54] evaluating the levels of soluble HLAs, it was found that the mean level of sHLA-II in CSF and saliva were equivalent and higher in the patient group, while sHLA-I levels were undetectable in saliva and CSF samples in patients with MS. This evidence concerns the gene HLA-S and myeloid sarcoma.